Background Transarterial valve intervention (TAVI) is valuable in high-risk patients, however, in case of left ventricular outflow tract (LVOT) obstruction, conventional surgery, including partial myectomy, is indicated. Case Description An 84-year-old female patient presented with increasing fatigue after TAVI in 2012, demonstrated a narrowed LVOT. Conventional surgery was performed, including...

Aortic valve stenosis is a well-recognized valvular problem in the aging population. Transcatheter aortic valve implantation (TAVI) is becoming an increasingly popular treatment alternative to surgical aortic valve replacement for frail elderly individuals with symptomatic severe aortic valve stenosis. There are multiple research reports documenting the effectiveness of TAVI in octogenarians; h...

Transcatheter aortic valve implantation (TAVI) has become the standard of care for elderly high-risk patients presenting severe and symptomatic aortic valve stenosis, while surgical aortic valve replacement (sAVR) is still considered as the treatment of choice for younger patients and patients with low and intermediate risk profiles (1,2). With more than 100,000 implants worldwide, TAVI has cha...

BACKGROUND & OBJECTIVES In recent years, emerging transcatheter aortic valve implantation (TAVI) has become an alternative for surgery. However, with advanced age, several co-morbid factors together with contrast agent usage can cause deterioration in renal function and increase in the risk of acute kidney injury (AKI) with poor prognosis in patients with AKI. Therefore, many patients cannot be...

BACKGROUND Transcatheter aortic valve implantation (TAVI) is a therapeutic option for high-risk patients with aortic stenosis. Procedural mortality remains high in comparison with conventional aortic valve replacement (AVR) because patients determined for TAVI are commonly denied conventional surgery. We aimed to evaluate access-related complications between the transfemoral (TF) and the transa...

BACKGROUND Recently, the use of transcatheter aortic valve implantation (TAVI) in inter-mediate-low risk patients has been evaluated in the PARTNER II randomized trial. However, in the last years, this therapy has been employed in this scenario with underreported results, as compared to surgical aortic valve replacement (SAVR). METHODS We enrolled 362 consecutive patients with severe symptoma...

Correspondence to Dr Stefan Toggweiler; [email protected] During the past few years, transcatheter aortic valve implantation (TAVI) has become a mature procedure, results have become reproducible and safety has increased. Nevertheless, the overall cost for TAVI is still higher than the cost for surgical aortic valve replacement (SAVR), mainly due to the higher price of the valve. In thi...

Background: Transcatheter Aortic Valve Implantation (TAVI) is beneficial in patients with symptomatic severe Stenosis (AS). There no consensus about the best anticoagulation strategy for a recent TAVI and atrial fibrillation (AF). Direct oral anticoagulants (DOACs) are effective to prevent embolic events significant lower incidence of bleeding. scarce evidence use these drugs undergoing TAVI.

The use of transcatheter aortic valve implantation (TAVI) to treat severe symptomatic aortic valve stenosis has increased exponentially in the last decade. This rapid expansion was seen predominantly in Western developed nations and has been fuelled by favorable results reported from a plethora of well-publicized randomized controlled trials, large retrospective series and national registries. ...

Transcatheter aortic valve implantation (TAVI) is an alternative method of treatment for severe symptomatic aortic stenosis in patients who are at high risk of surgical aortic valve replacement (AVR). In randomised clinical trials TAVI was shown to be superior to standard medical therapy in a cohort of inoperable patients and non-inferior to AVR in high-risk operable patients. Additionally, in ...